TRANSCAN-3: JOINT TRANSNATIONAL CALL FOR PROPOSALS JTC 2022-ISCIII. INSTITUTO DE SALUD CARLOS III 

PRESENTACIÓN DE SOLICITUDES 

Desde el 23 de mayo hasta el 18 de julio de 2022 a las 12:00h (horario peninsular)

RESUMEN DE LA CONVOCATORIA: 

El programa europeo TRANSCAN-3, dirigido a la financiación de proyectos de investigación colaborativos trasnacionales entre grupos de investigación del área del cáncer, lanza su primera convocatoria.

Específicamente, la convocatoria financiará proyectos bajo la temática: " "Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy". 

Los proyectos deberán ser de naturaleza traslacional, que cubran los siguientes objetivos de aplicación clínica:

  • Aim 1: Identification/validation of novel early diagnostic approaches. Early detection and diagnosis (ED&D) research seek to detect and diagnose consequential precancerous changes and cancer at the earliest possible point at which an effective intervention might be made, reducing the burden of late-stage disease. Any of the areas identified below can be eligible for funding:
    1. Identification and validation of novel biomarkers/signatures for HTTC, to better understand disease trajectory of very early/pre-cancerous lesions and help patient stratification in terms of risk, diagnosis/prognosis, response to treatment;
    2. Non-confirmatory clinical trials of ED&D technologies or approaches, in particular data and computation-driven approaches.

Proposals may include hypothesis-driven studies on a variety of biomarkers, e.g. structural, functional, molecular, genetic biomarkers; digital biomarkers are eligible only in combination with other bio-signatures. In all cases, a clear pathophysiological correlate and studies on human participants or tissue should be included in the proposal.

  • Aim 2: Identification/validation of novel therapeutic approaches. Although ED&D may significantly reduce the disease burden, HTTC are often characterised by an intrinsic resistance to available treatments. Therefore, it is of foremost importance to understand the biological processes that make these cancers “hard to treat”, and consequently to elaborate more effective therapeutic strategies, also to improve the patients’ quality of life. We welcome proposals aimed at:
    1. Identification and validation of novel therapeutical targets, based on better insights on resistance mechanisms, tumour heterogeneity, cellular plasticity, tumour microenvironment, immune responses, metastatic process, tumour dormancy. Novel targets should be evaluated in translational studies with regard to their impact on treatment efficacy and patient benefits. Any in-vitro model systems must closely relate to the human disease.
    2. Development of novel therapeutics/therapeutic approaches, through phase I and II clinical trials investigating combinations of available treatments, e.g. targeting multiple pathways, including immune/inflammatory, neoangiogenic and proliferative pathways, new therapeutics, new administration schemes, nutritional support, and other measures to maximise patient outcome and quality of life.
  • Aim 3: Development of novel drug delivery strategies. The overarching challenge associated with effective treatment of any cancer is to minimize undesired effects while maximizing therapeutic benefits. For HTTC two additional issues arise: (i) traditional targeted drug delivery strategies suffer from limited capacity of the delivery vehicles preventing sufficient drugs reaching the cancer site which restricts the efficacy of treatment; and (ii) to access the tumour the drug needs to cross endogenous barriers, such as the blood brain barrier and tissue stroma. Therefore, we welcome proposals that aim at developing novel drug delivery systems for HTTC by:
    1. achieving site-specific targeting; and/or
    2. controlling release rate.

 

REQUISITOS DE LOS SOLICITANTES

Para la participación será necesaria la formación de consorcios trasnacionales constituidos por un mínimo de tres y un máximo de seis entidades pertenecientes, al menos, a tres países diferentes entre los participantes en la convocatoria.

No se aceptará la participación de más de dos entidades pertenecientes a un mismo país, dentro de un mismo consorcio. 

Cada consorcio deberá involucrar a, al menos, un equipo de investigación básica o pre-clínica y un equipo clínico. 

Países participantes en la convocatoria: Austria, Bélgica, Canadá, Estonia, Francia, Alemania, Hungría, Irlanda, Israel, Italia, Letonia, Noruega, Polonia, Portugal, Rumanía, República Eslovaca, España, Taiwán y Turquía. 

CUANTÍA: 

Entre 175.000 y 250.000€

Principio del formulario

  • Máximo 175.000€ por cada socio español del proyecto.
  • Máximo 250.000€ si el IP español es el coordinador de la propuesta.

DURACIÓN

Máximo tres años.

Final del formulario

WEB DE LA AYUDA: 

https://transcan.eu/news-and-resources/updates/new-funding-opportunity-preannouncement.kl